Register No: Status: Public
|
|
- Maryann Lindsey
- 5 years ago
- Views:
Transcription
1 MANAGEMENT OF MENOPAUSE CLINICAL GUIDELINES Register No: Status: Public Developed in response to: RCOG guideline: Best Practice 2015 Contributes to CQC 11, 12 Consulted With Post/Committee/Group Date Miss Anita Rao/ Alison Cuthbertson Alison Cuthbertson Sally Larcombe Jan Medici Debbie Anderson Claire Fitzgerald Sarah Moon Clinical Directors for Women s and Children s Directorate Head of Midwifery/ Nursing Sister in Charge of Gynaecological Outpatients Sister in Charge of Gynaecological Outpatients Staff Nurse Gynaecological Outpatients Pharmacy Specialist Midwife for Guidelines and Audit May 2018 Professionally Approved By: Anita Rao Consultant Obstetrician May 2018 Version Number 1.0 Issuing Directorate Women s and Children s Ratified By DRAG Chairman s Action Ratified On 18 th June 2018 Trust Executive Sign Off Date July 2018 Implementation Date 16 th July 2018 Next Review Date May 2021 Author/Contact for Information Mrs Vidya Thakur, Consultant Obstetrician Policy to be followed by (target staff) Gynaecology and Theatre Staff Distribution Method Intranet & Website. Notified on Staff Focus Related Trust Policies (to be read in conjunction with) Standard Infection Prevention Hand Hygiene Clinical Record Keeping Standards Policy Human Tissue Disposal Document History: Version No: Authored/Reviewed by: Issue Date: 1.0 Vidya Thakur 16 th July
2 INDEX 1. Purpose 2. Background and Definitions 3. Symptoms of Menopause 4. Diagnosing Menopause 5. Diagnosing Premature Menopause 6. Assessment of Menopause 7. Information and Advice 8. Managing the Menopause without HRT 9. Managing the menopause with HRT 10. Referral Process 11. Equality and Diversity 12. Audit and Monitoring 13. Guideline Management 14. Communication 15. References 2
3 1.0 Purpose 1.1 To streamline the care pathway and services for women who present with menopausal symptoms. 2.0 Background and Definitions 2.1 Menopause is a biological stage in a woman's life when menstruation ceases permanently due to the loss of ovarian follicular activity. It occurs with the final menstrual period and is usually diagnosed clinically after 12 months of amenorrhoea. In the UK, the mean age of the natural menopause is 51 years, although this can vary between different ethnic groups. 2.2 Perimenopause, also called the 'menopausal transition' or 'climacteric', is the period before the menopause when the endocrinological, biological, and clinical features of approaching menopause commence. It is characterized by irregular cycles of ovulation and menstruation and ends 12 months after the last menstrual period. 2.3 Post menopause is the time after a woman has not had a period for 12 consecutive months. 2.4 Premature menopause, also called 'premature ovarian insufficiency' or 'premature ovarian failure', is usually defined as menopause occurring before the age of 40 years. 2.0 Symptoms of Menopause 2.1 Vasomotor symptoms (hot flushes and night sweats) are the most commonly reported symptoms, occurring in about 75% of postmenopausal women, with 25% of these being severely affected. Symptoms may resolve in 2 5 years, but the median duration is 7 years and sometimes longer. 2.2 Other symptoms include mood changes, musculoskeletal symptoms, urogenital symptoms, sleep disturbance, and sexual disorders 3.0 Risk of chronic disease after menopause 3.1 Women with untreated premature menopause and early perimenopause (menopause between the ages of 40 and 45 years) are at increased risk of mortality and serious morbidity, including cardiovascular disease (CVD), cognitive decline, dementia, parkinsonism, and osteoporosis. This increased risk is due to the menopausal decrease in oestrogen levels. 3
4 3.2 Postmenopausal women are at increased risk of osteoporosis, CVD, stroke, and atrophic changes in the vagina and bladder, due to oestrogen depletion as well as natural ageing. 4.0 Diagnosing Menopause 4.1 Diagnose the following without laboratory tests in otherwise healthy women aged over 45 years with menopausal symptoms: A. Perimenopause if the woman has vasomotor symptoms and irregular periods B. Menopause if the woman has not had a period for at least 12 months C. Menopause based on symptoms in women without a uterus 4.2 Consider using the follicle stimulating hormone (FSH) blood test to diagnose menopause in the following groups of women provided they are not taking combined oestrogen and progestogen contraception or high-dose progestogen, as the diagnostic accuracy of the FSH blood test may be confounded by these treatments: Women aged over 45 years with atypical symptoms Women between years with menopausal symptoms, including a change in their menstrual cycle Women younger than 40 years in whom premature menopause is suspected A pelvic examination should be performed only if clinically indicated and to exclude other possible causes of symptoms. 5.0 Diagnosing Premature Menopause 5.1 The diagnosis of premature menopause should take into account the woman s clinical history (for example previous medical or surgical treatment) and family history. 5.2 A. Diagnose premature menopause in women younger than 40 years based on: Menopausal symptoms, including no or infrequent periods (taking into account whether the woman has a uterus) and Elevated follicle stimulating hormone (FSH) levels on 2 blood samples taken 4 6 weeks apart. Do not use a serum FSH test to diagnose menopause in women using combined oestrogen and progestogen contraception or high-dose progestogen, as the diagnostic accuracy may be confounded by these treatments. B. If there is doubt about the diagnosis of premature menopause, consider anti-müllerian hormone testing after seeking specialist advice. Do not diagnose premature menopause on the basis of a single blood test 4
5 Do not routinely use anti-müllerian hormone testing to diagnose premature menopause. C. A pelvic examination should be performed only if clinically indicated and to exclude other possible causes of symptoms. 6.0 Assessment of Menopause 6.1 Assess her symptoms and their severity. This helps determine: The most suitable treatment (hormonal, non-hormonal, or non-pharmacological). The severity of the symptoms and the extent to which they are affecting the woman's quality of life. 6.2 Assess her risk of cardiovascular disease (CVD): Women with, or at increased risk of, CVD should have their cardiovascular risk factors managed. 6.3 Assess her risk of osteoporosis: Discuss the woman's expectations: Ask why she has consulted (for example concern regarding the cause of the symptoms). Ask if she would like treatment for her symptoms. 6.4 Investigations and examinations are not routinely indicated before starting hormone replacement therapy, unless: There is a sudden change in menstrual pattern, intermenstrual bleeding, postcoital bleeding, or postmenopausal bleeding arrange an urgent 2-week referral if a gynaecological cancer is suspected There is a personal or family history of venous thromboembolism consider arranging a thrombophilia screen, bearing in mind that a negative thrombophilia screen does not mean the woman is not at risk. There is a high risk of breast cancer consider referring for mammography. The woman has arterial disease or other risk markers for arterial disease a lipid profile may be useful. The woman has history, symptoms, or family history of gynaecological disease considers a pelvic examination. 5
6 7.0 Information and Advice 7.1 Information and advice as follows: An explanation of the stages of menopause. The common symptoms of the menopause. Available treatments for menopausal symptoms, including hormone replacement therapy (HRT), non-hormonal treatments (such as antidepressants), and nonpharmacological treatments (such as cognitive behavioural therapy [CBT] and relaxation techniques). The risks possible adverse effects, benefits, and expected duration of treatment with HRT. Advice on bone health (especially for women diagnosed with premature menopause). Advice on the importance of keeping up to date with nationally recommended health screening, including: The NHS Breast Screening Programme that is offered every 3 years to women aged 50 years or over. The Cervical Screening Programme which is available for all women aged 25 years and over with a frequency of routine 3-yearly recall between years of age, then 5-yearly recall until aged 65 years. Advice on contraception, including that HRT does not provide contraception and that a woman is considered potentially fertile for 2 years after her last menstrual period if she is younger than 50 years of age, and for 1 year if she is over 50 years of age. 7.2 Information on support groups, such as: Menopause UK ( a network of groups and organizations which represent and support women affected by menopause. Menopause Matters ( provides information on the menopause, menopausal symptoms, and treatment options. The Daisy Network ( a nationwide support group for women who have suffered a premature menopause. 7.3 Give advice on lifestyle modifications to reduce menopausal symptoms. For example: Hot flushes and night sweats regular exercise, weight loss (if applicable), wearing lighter clothing, sleeping in a cooler room, reducing stress, and avoiding possible triggers (such as spicy foods, caffeine, smoking, and alcohol). 6
7 Sleep disturbances avoiding exercise late in the day and maintaining a regular bedtime. Mood and anxiety disturbances adequate sleep, regular physical activity, and relaxation exercises. Cognitive symptoms exercise and good sleep hygiene. 8.0 Managing the Menopause without HRT 8.1 Advise on lifestyle modification to reduce menopausal symptoms. 8.2 If lifestyle modifications are ineffective, consider one of the following: 8.3 Prescribe non-hormonal and/or non-pharmacological treatments for symptom relief: For vasomotor symptoms, consider a 2-week trial of fluoxetine (20 mg daily), citalopram (20 mg daily), or venlafaxine (37.5 mg twice a day). Note that the use of antidepressants for treating menopausal symptoms is off-label. For vaginal dryness, prescribe a vaginal lubricant or moisturizer, such as Replens MD. For sexual dysfunction, seek specialist advice regarding the use of testosterone supplementation (off-label use). Obtain (and document) informed consent before prescribing testosterone for this indication. For psychological symptoms, such as mood disturbance, anxiety, and depression, consider self-help groups, cognitive behavioural therapy (CBT), or antidepressants. Note that there is no clear evidence for antidepressants to ease low mood in menopausal women who have not been diagnosed with depression. For more information, see the CKS topics on Depression and Generalized anxiety disorder Refer the woman to a healthcare professional with expertise in menopause. Advise the woman to return if her symptoms persist or worsen. For women considering complementary therapies, explain that the quality, purity, and constituents of these products may be unknown. Although there is some evidence that isoflavones and black cohosh may relieve vasomotor symptoms, their safety is unknown and different preparations may vary. 8.4 Review the woman at 3 months, then annually thereafter unless there are clinical indications for an earlier review (such as treatment ineffectiveness or adverse effects). At the review: Assess efficacy and tolerability of treatment(s). Reinforce information and lifestyle advice. 7
8 If the woman is symptom-free on treatment, consider a trial withdrawal of the antidepressant treatment after 1 2 years of treatment. Advise that symptoms may recur once treatment is stopped. The use of vaginal moisturizers and lubricants may be continued indefinitely. 8.5 Refer the woman to a healthcare professional with expertise in menopause if treatments do not improve menopausal symptoms. 9.0 Managing the menopause with HRT 9.1 If a woman chooses to use hormone replacement therapy (HRT), following a discussion on the risks, possible adverse effects, and benefits, and there are no contraindications to its use: 9.2 Advise on lifestyle modifications to reduce menopausal symptoms. 9.3 Prescribe the most suitable type of HRT based on her symptoms: For vasomotor symptoms: In woman with a uterus, offer an oral or transdermal combined (oestradiol plus progestogen) HRT preparation. In women without a uterus, offer an oral or transdermal oestrogen-only preparation. In women diagnosed with premature menopause, offer sex steroid replacement with a choice of HRT or a combined oral contraceptive (unless contraindicated) For effects on mood, offer a choice of oral or transdermal HRT preparations as above. Consider referring the woman for a trial of cognitive behavioural therapy (CBT) to alleviate low mood and anxiety. For urogenital symptoms, manage according to the specific symptom: For women with urogenital atrophy (including those already using systemic HRT), offer low-dose vaginal oestrogen. Continue treatment for as long as needed to relieve symptoms. For women with vaginal dryness, advise that moisturisers and lubricants can be used alone or in addition to vaginal oestrogen. For sexual dysfunction, seek specialist advice regarding the use of testosterone supplementation (off-label use). Obtain (and document) informed consent before prescribing testosterone for this indication. For women considering complementary therapies, explain that the quality, purity, and constituents of these products may be unknown. 8
9 Although there is some evidence that isoflavones and black cohosh may relieve vasomotor symptoms, their safety is unknown and different preparations may vary. 9.4 Advise women with premature menopause that they should not use HRT as a contraceptive Review the woman at 3 months, then annually thereafter unless there are clinical indications for an earlier review (such as treatment ineffectiveness or adverse effects). At the review: 9.6 Assess efficacy and tolerability of treatment(s). If low-dose vaginal oestrogen does not relieve symptoms, consider increasing the dose after seeking specialist advice from a healthcare professional with expertise in menopause. 9.7 Reinforce information and lifestyle advice 9.8 If HRT was started in the perimenopause, discuss the option of changing the treatment regimen and/or reducing the dose of oestrogen in the HRT (with longer duration of treatment). 9.9 Be aware that HRT may need to be stopped immediately in certain circumstances 9.10 Consider referring the woman to a healthcare professional with expertise in menopause if: Treatment is ineffective. They have ongoing troublesome adverse effects. There are 'red flag' symptoms such as unexplained bleeding arrange an urgent 2- week referral if a gynaecological cancer is suspected For vasomotor symptoms, most women require 2 5 years of HRT, but some women may need longer. This judgement should be made on a case-by-case basis with regular attempts to discontinue treatment. Symptoms may recur for a short time after stopping HRT Topical (vaginal) oestrogen may be required long term. Regular attempts (at least annually) to stop treatment are usually made. Symptoms may recur once treatment has stopped Women with premature menopause usually take HRT up to the average age of the natural menopause (51 years), after which the need for HRT should be reassessed. Some women will still be symptomatic. 9
10 9.14 Offer women who wish to stop HRT a choice of gradually reducing or immediately stopping treatment 9.15 Gradually reducing or immediately stopping HRT makes no difference to their symptoms in the longer term Gradually reducing HRT may limit recurrence of symptoms in the short-term Symptoms of urogenital atrophy often come back when treatment with vaginal oestrogen is stopped Referral Process 10.1 Women with complex medical history requesting HRT, please refer to the local menopause/hrt lead This pathway will ensure that medical practitioners who object to termination of pregnancy will not be involved in the management of these women and thus the care of these women will not be affected by dissenters to the process Equality and Diversity 11.1 Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals Audit and Monitoring 12.1 Audit of compliance with this guideline will be considered on an annual audit basis in accordance with the Clinical Audit Strategy and Policy (register number 08076), the Corporate Clinical Audit and Quality Improvement Project Plan and the Maternity annual audit work plan; to encompass national and local audit and clinical governance identifying key harm themes. The Women s and Children s Clinical Audit Group will identify a lead for the audit The findings of the audit will be reported to and approved by the Multi-disciplinary Risk Management Group (MRMG) and an action plan with named leads and timescales will be developed to address any identified deficiencies. Performance against the action plan will be monitored by this group at subsequent meetings The audit report will be reported to the monthly Directorate Governance Meeting (DGM) and significant concerns relating to compliance will be entered on the local Risk Assurance Framework Key findings and learning points from the audit will be submitted to the Clinical Governance Group within the integrated learning report Key findings and learning points will be disseminated to relevant staff. 10
11 13.0 Guideline Management 13.1 As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust s intranet site Quarterly memos are sent to line managers to disseminate to their staff the most currently approved guidelines available via the intranet and clinical guideline folders, located in each designated clinical area Guideline monitors have been nominated to each clinical area to ensure a system whereby obsolete guidelines are archived and newly approved guidelines are now downloaded from the intranet and filed appropriately in the guideline folders. Spot checks are performed on all clinical guidelines quarterly Quarterly Clinical Practices group meetings are held to discuss guidelines. During this meeting the practice development midwife can highlight any areas for further training; possibly involving workshops or to be included in future skills and drills mandatory training sessions 14.0 Communication 14.1 A quarterly maternity newsletter is issued and available to all staff including an update on the latest guidelines information such as a list of newly approved guidelines for staff to acknowledge and familiarise themselves with and practice accordingly Approved guidelines are published monthly in the Trust s Staff Focus that is sent via to all staff Approved guidelines will be disseminated to appropriate staff quarterly via Regular memos are posted on the Guideline and Audit notice boards in each clinical area to notify staff of the latest revised guidelines and how to access guidelines via the intranet or clinical guideline folders Approved guidelines will be disseminated to appropriate staff quarterly via Regular memos are posted on the Risk Management notice boards in each clinical area to notify staff of the latest revised guidelines and how to access guidelines via the intranet or clinical guideline folders References National Institute for Clinical Excellence (2015) Menopause: diagnosis and management. NICE; NG23; November. Royal College of Obstericians and Gynaecologists (2006) Alternatives to HRT for symptoms of the menopause. RCOG: May. National Institute for Clinical Excellence (2017) Menopause. Quality Standard (QS143). NICE: February. 11
Menopause: diagnosis and management NICE guideline NG23. Published November 2015
Menopause: diagnosis and management NICE guideline NG23 Published November 2015 1 Full title: Menopause : diagnosis and management Available at: http://www.nice.org.uk/guidance/ng23 Guideline published
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationPRESS RELEASE. NICE issues first guideline on menopause to stop women suffering in silence
EMBARGOED UNTIL: 00.01hrs, THURSDAY 12 NOVEMBER 2015 PRESS RELEASE NICE issues first guideline on menopause to stop women suffering in silence More than a million women could benefit from the first NICE
More informationNICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23
Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More informationPrescribing advice for the management of menopause in primary care
Prescribing advice for the management of menopause in primary care This guidance contains suggested advice for the management and treatment of women experiencing symptoms of menopause. It applies to Camden
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationMenopause & HRT. Rosie & Alex. Image:
Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationReal life issues & answers: The hormonal patient Defining best practice, 5 key issues & case study
Real life issues & answers: The hormonal patient Defining best practice, 5 key issues & case study Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk Case Number 1 - Claire Age
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationMenopause - a summary of management
Page 1 of 5 Menopause - a summary of management Original article by: May Su Resources Menopause treatment algorithm The Jean Hales Foundation for women's heath. Menopause, a treatment algorithm. (Australian
More informationBefore you prescribe
Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT
More informationDeb Cobie Judy Evans Professionally Approved By Dr Saravanan Consultant Lead for Risk Management June 2009
TREATMENT OF NEONATAL HYPOGLYCAEMIA Developed in response to: Contributes to CQC Standards No CLINICAL GUIDELINES Register No: 04219 Status: Public Intrapartum NICE Guidelines RCOG guideline C5a Consulted
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationBy J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University
By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University Cessation of menstruation as a result of the aging process of or surgical removal of the ovaries; change
More information11/15/2017. Update on HRT. Highgate Private Hospital (Barnet Hospital) Women s Health. Menopause
Update on HRT Miss Moneli Golara Consultant Obstetrician and Gynaecologist MBBS, FRCOG Highgate Private Hospital (Barnet Hospital) E: lauren@medicaladministration.co.uk Women s Health Life expectancy of
More informationYear: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy
Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull
More informationTopics. Periods Menopause & HRT Contraception Vulva problems
Girls stuff Topics Periods Menopause & HRT Contraception Vulva problems Menorrhagia Excessive menstrual loss occurring with regular or irregular cycles Ovulatory Anovulatory Usual blood loss 30-40ml per
More informationMENOPAUSE / COMPLEX CONTRACEPTION / MEDICAL GYNAECOLOGY CLINICAL SERVICES AT CHALMERS
MENOPAUSE / COMPLEX CONTRACEPTION / MEDICAL GYNAECOLOGY CLINICAL SERVICES AT CHALMERS We welcome referrals of complex women and these should be for the attention of Dr Ailsa Gebbie. Details of receptor
More informationMenopause & HRT. Matt McKenna Elliot Davis
Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More information22/09/2014. Menopause Management. Menopause. Menopause symptoms
Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):
More informationWhat is the menopause?
Information for you Alternatives to hormone replacement therapy for symptoms of the menopause Published in December 2011 This information is for you if you are considering alternatives to hormone replacement
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More informationCommunity Gynaecology. Top Tips for GPs
Community Gynaecology Top Tips for GPs Top Tips for GPs Case Scenarios- common referral themes 6 topics What you can do in Primary Care to avoid or before referral. What we don t need to see Triage ensures
More informationOhio Northern University HealthWise. Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018
Women s Health Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018 Let Your Body Empower You! National Women s Health Week Polycystic Ovary Syndrome Page 2 Breast
More informationThrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor
Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service
More informationWestern Locality Shared care information ~ Gonadorelin Analogues (Gnrh)
Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Specialist: Please complete the Shared Care letter sending a request to GP (see bottom of the page) April 2013 GP: Please indicate
More informationGUIDE TO WOMEN S HEALTH
GUIDE TO WOMEN S HEALTH Women s health According to the World Health Organisation (WHO) women outlive men by approximately 6 to 8 years on average and represent the majority of the population aged 85 or
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationHeavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist
Heavy Menstrual Bleeding Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist Why is HMB so important? 1:20 women aged 30-49 consult their GP with HMB Once referred to gynaecologist, surgical
More informationClinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164
More informationMenopause Matters. Equity Office Staff Seminar 14 November 2018
Menopause Matters Equity Office Staff Seminar 14 November 2018 1 What to expect at menopause How to manage symptoms Support at work Dr Janice Brown Medical lead, The University of Auckland NZ representative,
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationDr Catherine Black. Head of WOOMB NZ
Dr Catherine Black Head of WOOMB NZ HRT AND NATURAL FERTILITY REGULATION Dr Catherine Black MB ChB DCH FRNZCGP Head of WOOMB NZ Summary Physiology of menopause Managing fertility Symptoms of menopause
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationMenopause Symptoms and Management: After Breast Cancer
Menopause Symptoms and Management: After Breast Cancer An Educational Webinar for Patients and their Caregivers Wen Shen, MD, MPH Division of Gynecologic Specialties July 27, 2018 1 Disclosure I have a
More informationInformation for you. Managing premenstrual syndrome (PMS) What is PMS?
Managing premenstrual syndrome (PMS) Information for you Published in August 2009 What is PMS? Premenstrual syndrome or PMS is the name given to a collection of physical and emotional symptoms that can
More informationPost Reproductive Health Joint RCOG/BMS Meeting Wednesday 31 October _ Thursday 1 November 2018
Post Reproductive Health Joint RCOG/BMS Meeting Wednesday 31 October _ Thursday 1 November 2018 Overview This meeting endeavours to provide answers to the most commonly asked and most difficult questions
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationUterine artery embolisation for treating adenomyosis
Uterine artery embolisation for treating Issued: December 2013 guidance.nice.org.uk/ipg NICE has accredited the process used by the NICE Interventional Procedures Programme to produce interventional procedures
More informationNeuroendocrine Evaluation
Elizabeth Lee Vliet, M.D. Medical Director Neuroendocrine Evaluation When women have health concerns they usually prefer to discuss them with another woman. Dr. Vliet is a national expert on hormone-related
More informationHormone Treatments and the Risk of Breast Cancer
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State (BCERF) Updated July 2002 Hormone Treatments and the Risk of Breast Cancer 1) Hormone Treatment After Menopause
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationPolycystic ovary syndrome (PCOS)
Information for patients Polycystic ovary syndrome (PCOS) What is polycystic ovary syndrome? Polycystic ovary syndrome (PCOS) is a condition which can affect a woman s menstrual cycle, fertility, hormones
More informationInformation for you. What is polycystic ovary syndrome? Polycystic ovary syndrome: what it means for your long-term health
aashara Polycystic ovary syndrome: what it means for your long-term health Information for you Published in February 2005, minor amendments in June 2005 Revised 2009 What is polycystic ovary syndrome?
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationManaging premenstrual syndrome (PMS)
Information for you Published in March 2018 Managing premenstrual syndrome (PMS) About this information This information is for you if you have, or think you have, premenstrual syndrome (PMS) and want
More informationSurgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk
Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationHormone therapy. Where are we now? Menopause. Menopause symptoms. Background. Objective. Discussion. Keywords: menopause; hormone therapy
Menopause Helena J Teede Amanda Vincent Hormone therapy Where are we now? Background Menopause is the permanent cessation of menstruation resulting from loss of ovarian follicular activity. The characteristic
More informationThis information can be found by going to Hot Flashes
Winsor Pilates - Official Site Reach physical and mental health while sculpting your... www.winsorpilates.com ML Speakers Group -Women's Health Today Book an exciting speaker to make your event special.
More informationBy Dr Rukhsana Hussain 5 th April 2016
By Dr Rukhsana Hussain 5 th April 2016 1. Is it indicated? Vasomotor symptoms (flushes/sweats) Vaginal atrophy Cycle control (In perimenopause consider low dose COCP (age
More informationWhat is polycystic ovary syndrome? What are polycystic ovaries? What are the symptoms of PCOS?
What is polycystic ovary syndrome? Polycystic ovary syndrome (PCOS) is a condition which can affect a woman s menstrual cycle, fertility, hormones and aspects of her appearance. It can also affect your
More informationInformation for you. Managing premenstrual syndrome (PMS) What is PMS?
Managing premenstrual syndrome (PMS) Information for you Published in August 2009 What is PMS? Premenstrual syndrome or PMS is the name given to a collection of physical and emotional symptoms that can
More informationGynaecology Cancer Red Flags. Dr Dina Bisson Consultant Obstetrician and Gynaecologist Southmead Hospital North Bristol NHS Trust 27 April 2017
Gynaecology Cancer Red Flags Dr Dina Bisson Consultant Obstetrician and Gynaecologist Southmead Hospital North Bristol NHS Trust 27 April 2017 Gynaecological Cancers Endometrial Cancer Ovarian Cancer Cervical
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationNICE offer to STPs: CVD prevention
NICE offer to STPs: CVD prevention Zoe Girdis Regional Technical Adviser South of England and Channel Islands NICE support for STPs Based on the best available evidence of what works and is costeffective,
More informationSex, hormones and the heart
Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards
More informationGuideline scope Hypertension in adults (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Hypertension in adults (update) This guideline will update the NICE guideline on hypertension in adults (CG127). The guideline will be
More informationType: Clinical Guideline Register No: Status: Public MANAGEMENT OF ACUTE ASTHMA IN CHILDREN MORE THAN 2 YEARS IN HOSPITAL
MANAGEMENT OF ACUTE ASTHMA IN CHILDREN MORE THAN 2 YEARS IN HOSPITAL Type: Clinical Guideline Register No: 09055 Status: Public Developed in Response to: Best practice CQC Fundamental Standard: 9, 12,
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More informationSERVICE SPECIFICATION 6 Conservative Management & End of Life Care
SERVICE SPECIFICATION 6 Conservative Management & End of Life Care Table of Contents Page 1 Key Messages 2 2 Introduction & Background 2 3 Relevant Guidelines & Standards 2 4 Scope of Service 3 5 Interdependencies
More informationMENOPAUSE - WHAT TO EXPECT CONCLUSION WEB LINKS
NOTES CONCLUSION The average Canadian woman can expect to live to 80 years of age or older. This means you may live more than one-third of your life after menopause. Knowing what to expect and how to care
More informationCervical Cancer - Suspected
Cervical Cancer - Suspected Presentation for patients Asymptomatic presentation Symptomatic presentation History and examination Consider differential diagnoses RED FLAG! Cervix appears normal after examination
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationConsulted With: Post/Committee/Group: Date: John Crome Drug and Alcohol Liaison Emergency Care
THE MANAGEMENT OF OPIOID WITHDRAWAL IN ADULT PATIENTS Type: Clinical Guideline Register No: 18007 Status: Public on ratification Developed in response to: Contributes to CQC Outcome number: 12 Best practice
More informationthe IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to
your guide to Helping you choose the method of contraception that s best for you IUD IUD the e IUD IU IUD the IUD 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that s put
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Step 3: GAD with marked functional impairment or that has not improved after step 2 interventionsentions bring together everything NICE says on a topic in an interactive flowchart. are interactive and
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationMMPr001 EMERGENCY CONTRACEPTION PROTOCOL
MMPr001 EMERGENCY CONTRACEPTION PROTOCOL Table of Contents MMPr001 EMERGENCY CONTRACEPTION PROTOCOL... 1 Why we need this Protocol... 2 What the Protocol is trying to do... 2 Which stakeholders have been
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationEstrogen (conjugated estrogens & ethinyl estradiol) Addition to the List
Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Note: Commonly prescribed medication. Literature question Is estrogen effective and safe? Are conjugated estrogens effective and
More informationEndometriosis Information Leaflet
Endometriosis Information Leaflet What is Endometriosis? Endometriosis is a condition where tissue similar to the lining of the womb (endometrium) is found outside the womb. About 1 out of 10 women of
More informationManagement of Patients With Premature Ovarian Insufficiency
Management of Patients With Premature Ovarian Insufficiency Prof. Dr. H. Cavidan Gülerman Sağlık Bilimleri Üniversitesi Ankara Dr. Zekai Tahir Burak SUAM XII. Türk Alman Jinekoloji Kongresi 28 Nisan 2018
More informationLevosert levonorgestrel 20mcg/24hour intrauterine device
Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert
More informationHORMONES AND YOUR HEALTH Charlie Tucker Pharm. D
HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D All of the hormones in your body are designed to work together. This is God s plan. Therefore, if one is altered, or deficient, it will affect the actions
More informationRequesting Adult Transthoracic Echocardiograms with Bubble Study
Requesting Adult Transthoracic Echocardiograms with Bubble Study Type: Clinical Guideline Register No: 11050 Status: Public Developed in response to: Contributes to CQC Core Outcome The need to prevent
More informationJOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH How to cite this article: CHOWTA N K,SEBASTIAN J,CHOWTA M N.COMPARATIVE STUDY OF MENOPAUSAL SYMPTOMS IN POST MENOPAUSAL AND PERIMENOPAUSAL WOMEN.Journal of Clinical
More informationPolycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome (PCOS) What are Polycystic Ovaries? Polycystic ovaries are slightly larger than normal ovaries and have twice the number of follicles (small cysts). Polycystic ovaries are very
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationPreventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE
Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE DR GARY FENTIMAN, CLINICAL LEADER COLPOSCOPY, N C S P TAKE-HOME LESSONS Vaccination is Primary Prevention for Cervical Cancer Women
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationCancer Genetics Unit Patient Information
Chemoprevention for women at an increased risk of familial breast cancer Cancer Genetics Unit Patient Information What is chemoprevention? Chemoprevention describes drugs that are used to reduce the risk
More informationGP Education Series Women s cancers. GP Education Day 11 July 2016
GP Education Series Women s cancers GP Education Day 11 July 2016 Sexual Consequences of Treatment for Women s Cancers Dr Isabel White Clinical Research Fellow in Psychosexual Practice The Royal Marsden
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More information